Drug Trial Radar · NCT06340633
SPI-1005 in Adults Receiving Cochlear Implant
Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Sound Pharmaceuticals, IncorporatedIndustry
- Sponsor type
- Industry
- Collaborators
- Med-El Corporation
- First posted
- Apr 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn about the effects of drug SPI-1005 in adults receiving a cochlear implant with a long electrode array (FLEX26 or greater) from MED-EL Cochlear Implant Systems into one ear. The main question this clinical trial aims to answer is: Is drug SPI-1005 safe and well-tolerated in adults receiving a cochlear implant, and/or what medical problems might participants experience when taking drug SPI-1005? The clinical trial will also measure the effects of SPI-1005 on hearing, word recognition, speech discrimination, tinnitus, and vertigo outcomes after receiving a cochlear implant. The purpose for this and future clinical trials is to learn whether SPI-1005 can prevent or treat these side effects after receiving a cochlear implant. Participants will take drug SPI-1005 or placebo (a look-alike substance that contains no drug) for 6 months, starting 2 days before receiving the cochlear implant. There are 5 required in-clinic visits over 6 months for audiology and other tests. The effects of SPI-1005 will be compared to the placebo (the look-alike substance that contains no drug) to study what effects SPI-1005 might have.
Conditions
- Hearing Loss
- Cochlear Trauma
Interventions
EbselenDrug
Glutathione peroxidase mimetic
PlaceboDrug
Matching placebo containing excipients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment Emergent Adverse Events (TEAE)Time frame: 12 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of Iowa
Iowa City, Iowa · Recruiting
Ohio State University
Columbus, Ohio · Recruiting
Thomas Jefferson University
Philadelphia, Pennsylvania · Recruiting
Medical University of South Carolina
Charleston, South Carolina · Recruiting
University of Texas Southwestern
Dallas, Texas · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.